Lovastatin as a Potential Modulator of Apoptosis in Chronic Obstructive Pulmonary Disease (COPD)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
This study will test whether lovastatin helps to modify lung inflammation in patients with COPD (Chronic Obstructive Pulmonary Disease).
Condition or disease
Chronic Obstructive Pulmonary Disease (COPD)
Drug: LovastatinDrug: Placebo
The impact of lovastatin, 40mg by mouth once daily on biological and clinical outcomes will be evaluated in an exploratory 16-week comparative treatment efficacy trial in 44 adult former smokers with established COPD of moderate severity. This trial employs a longitudinal randomized, parallel-arm, double-blind, placebo-controlled design using biomarkers of airway inflammation as the primary outcomes of interest.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
45 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Adult (≥45 years) former smokers with ≥ 10 pack-years of cigarette smoking
FEV1/FVC ratio < 70%
Post-bronchodilator FEV1 between 50% and 80% of predicted if undergoing bronchoscopy, or between 30% and 80% of predicted if undergoing induced sputum only
DLco/VA < 80% predicted
Ability to perform and adhere to study protocol
ability to provide informed consent.
Asthma or other comorbid lung disease,
Hypoxemia (PaO2 < 55 mmHg or SpO2 < 88% on room air), if undergoing bronchoscopy
Exacerbation of COPD within the last 6 weeks
Upper or lower respiratory tract infection within the last 6 weeks
Significant coronary artery disease as reflected by unstable angina, myocardial infarction or angioplasty/stenting/bypass surgery within 6 months
Current use of HMG-coA-reductase inhibitors
Current use of inhaled corticosteroid
Concurrent use of other Cyp3A4 (isoform of cytochrome P450) inhibitors
History of adverse reaction to HMG-coA-reductase inhibitors (rhabdomyolysis, hepatitis)
For patients undergoing bronchoscopy, any contraindication to fiberoptic bronchoscopy or conscious sedation, including abnormalities of the platelet count, prothrombin time or partial thromboplastin time.